




# U.S. MPV Vaccine Supply Strategy

Data as of December 13, 2022




## Key Milestones

- JYNNEOS vaccine was licensed in **September 2019**
- 1.4 million** vials were purchased in **2020**
- 5.5 million** additional vials have been ordered since **May 2022**




## Planned by End of 2022: Approximately 2.2 Million Total Vials




All projections are based on assumptions of successful fills, release testing to support use, and final release by the FDA

## Total Vaccine Vials Distributed



Source: ASPR (<https://aspr.hhs.gov/SNS/Pages/JYNNEOS-Distribution.aspx>)

## Total Vaccine Doses Administered and Reported to CDC\*



Source: CDC ([https://www.cdc.gov/poxvirus/monkeypox/response/2022/vaccines\\_data.html](https://www.cdc.gov/poxvirus/monkeypox/response/2022/vaccines_data.html))

\* Vaccine doses administered includes data from 57 jurisdictions reporting data to CDC as of December 13, 2022: Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming, Guam, Mariana Islands, Puerto Rico, Virgin Islands, New York City, and Philadelphia